keyword
https://read.qxmd.com/read/38499457/pracinostat-combined-with-azacitidine-in-newly-diagnosed-adult-acute-myeloid-leukemia-aml-patients-unfit-for-standard-induction-chemotherapy-primula-phase-iii-study
#21
JOURNAL ARTICLE
Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced age, comorbidities, and/or risk factors. However, response rates and survival remain dismal. Pre-clinical studies indicate the epigenetic combination of HMAs and HDAC inhibitors induce re-expression of silenced genes synergistically. The activity of pracinostat, an oral pan-HDAC inhibitor, has been shown in xenograft tumor models of AML and promising efficacy was seen in a Phase 2 study...
March 12, 2024: Leukemia Research
https://read.qxmd.com/read/38497960/severe-sepsis-during-treatment-for-childhood-leukemia-and-sequelae-among-adult-survivors
#22
JOURNAL ARTICLE
Kathryn P Goggin, Lu Lu, Danielle E Lee, Carrie R Howell, Deokumar Srivastava, Tara M Brinkman, Gregory T Armstrong, Nickhill Bhakta, Leslie L Robison, Mathew J Ehrhardt, Melissa M Hudson, Kevin R Krull, Ching-Hon Pui, Jeffrey Rubnitz, Kirsten K Ness, Joshua Wolf
IMPORTANCE: Children undergoing treatment for leukemia are at increased risk of severe sepsis, a dysregulated immune response to infection leading to acute organ dysfunction. As cancer survivors, they face a high burden of long-term adverse effects. The association between sepsis during anticancer therapy and long-term organ dysfunction in adult survivors of childhood cancer has not been examined. OBJECTIVE: To determine whether severe sepsis during therapy for leukemia in childhood is associated with subsequent chronic health conditions in adult survivors...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38495641/factors-influencing-family-resilience-in-adult-patients-with-acute-leukemia-undergoing-chemotherapy-a-qualitative-study
#23
JOURNAL ARTICLE
Xuhan Sun, Yuqing Wang, Xinyu Lu, Shuyu Zhang, Yuxi Zhang
OBJECTIVE: To explore the factors influencing family resilience in adult patients with acute leukemia undergoing chemotherapy, with the aim of providing a theoretical basis for the development of strategies to strengthen their family resilience. METHODS: A descriptive phenomenological qualitative research method was used to select 11 adult acute leukemia chemotherapy patients for semi-structured interviews. Colaizzi 7-step analysis and NVivo 12.0 were used to summarize information and refine themes...
April 2024: Asia-Pacific Journal of Oncology Nursing
https://read.qxmd.com/read/38494578/effectiveness-and-safety-of-primary-prophylaxis-with-g-csf-after-induction-therapy-for-acute-myeloid-leukemia-a-systematic-review-and-meta-analysis-of-the-clinical-practice-guidelines-for-the-use-of-g-csf-2022-from-the-japan-society-of-clinical-oncology
#24
JOURNAL ARTICLE
Tomoya Maeda, Yuho Najima, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo, Dai Maruyama, Tatsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano
Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers...
March 18, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38493755/investigations-of-the-prognostic-value-of-runx1-mutation-in-acute-myeloid-leukemia-patients-data-from-a-real-world-study
#25
JOURNAL ARTICLE
Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Yan-Li Xu, Kai-Wen Tan, Yan-Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Song-Bai Liu, Jia-Jun Qi, Hai-Ping Dai, Sheng-Li Xue
RUNX1 is one of the recurrent mutated genes in newly diagnosed acute myeloid leukemia (AML). Although historically recognized as a provisional distinct entity, the AML subtype with RUNX1 mutations (AML-RUNX1mut ) was eliminated from the 2022 WHO classification system. To gain more insight into the characteristics of AML-RUNX1mut , we retrospectively analyzed 1065 newly diagnosed adult AML patients from the First Affiliated Hospital of Soochow University between January 2017 and December 2021. RUNX1 mutations were identified in 112 patients (10...
March 12, 2024: Leukemia Research
https://read.qxmd.com/read/38492861/sting-activating-cyclic-dinucleotide-manganese-nanoparticles-evoke-robust-immunity-against-acute-myeloid-leukemia
#26
JOURNAL ARTICLE
Marisa E Aikins, Xiaoqi Sun, Hannah Dobson, Xingwu Zhou, Yao Xu, Yu Leo Lei, James J Moon
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults with a 5-year survival rate of 30.5%. These poor patient outcomes are attributed to tumor relapse, stemming from ineffective innate immune activation, T cell tolerance, and a lack of immunological memory. Thus, new strategies are needed to activate innate and effector immune cells and evoke long-term immunity against AML. One approach to address these issues is through Stimulator of Interferon Genes (STING) pathway activation, which produces Type I Interferons (Type I IFN) critical for innate and adaptive immune activation...
March 20, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38485870/impact-of-cyp1a1-variants-on-the-risk-of-acute-lymphoblastic-leukemia-evidence-from-an-updated-meta-analysis
#27
JOURNAL ARTICLE
Imen Frikha, Rim Frikha, Moez Medhaffer, Hanen Charfi, Fatma Turki, Moez Elloumi
OBJECTIVE: Our study aimed to investigate the association between cytochrome P450 1A1 (CYP1A1) polymorphisms (T3801C and A2455G) and acute lymphoblastic leukemia (ALL) risk, considering genetic models and ethnicity. MATERIALS AND METHODS: PubMed, Embase, Web of Knowledge, Scopus, and the Cochrane electronic databases were searched using combinations of keywords related to CYP1A1 polymorphisms and the risk of ALL. Studies retrieved from the database searches underwent screening based on strict inclusion and exclusion criteria...
March 4, 2024: Blood Research
https://read.qxmd.com/read/38481242/uncovering-the-cellular-and-omics-characteristics-of-natural-killer-cells-in-the-bone-marrow-microenvironment-of-patients-with-acute-myeloid-leukemia
#28
JOURNAL ARTICLE
Leisheng Zhang, Yunyan Sun, Chun-E Xue, Shuling Wang, Xianghong Xu, Chengyun Zheng, Cunrong Chen, Dexiao Kong
BACKGROUND: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy and the most frequently acute leukemia of stem cell precursors and the myeloid derivatives in adult. Longitudinal studies have indicated the therapeutic landscape and drug resistance for patients with AML are still intractable, which largely attribute to the deficiency of detailed information upon the pathogenesis. METHODS: In this study, we compared the cellular phenotype of resident NK cells (rAML-NKs, rHD-NKs) and expanded NK cells (eAML-NKs, eHD-NKs) from bone marrow of AML patients (AML) and healthy donors (HD)...
March 14, 2024: Cancer Cell International
https://read.qxmd.com/read/38480517/sequelae-and-post-thrombotic-syndrome-after-venous-thromboembolism-in-acute-lymphoblastic-leukemia-survivors-treated-on-the-nopho-all2008-protocol
#29
JOURNAL ARTICLE
Merete Dam, Line Stensig Lynggaard, Ólafur G Jónsson, Sonata Saulyte Trakymiene, Katrin Palk, Kirsten Jarvis, Liv Andrés-Jensen, Ruta Tuckuviene, Birgitte Klug Albertsen
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post-thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from 0% to 70%, reflecting very heterogenous cohorts and assessment tools. We aimed to estimate sequelae, including PTS and QoL in children and adults (<45 years old) who had a DVT during ALL treatment...
March 13, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38478303/integrating-full-bayesian-inference-and-student-s-t-distribution-method-for-enhanced-outlier-handling-in-caffeine-population-pharmacokinetics-assessing-drug-drug-interactions-with-enasidenib-in-relapsed-or-refractory-aml-and-mds-patients
#30
JOURNAL ARTICLE
Yiming Cheng, Shengnan Du, Hongxiang Hu, Xiaomin Wang, Leon Carayannopoulos, Yan Li
As the first-in-class, selective, and potent inhibitor of the isocitrate dehydrogenase-2 (IDH2) mutant protein, enasidenib was approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Known for its interactions with various cytochrome P450 (CYP) enzymes and transporters in vitro, a clinical pharmacokinetics (PK) trial was initiated to assess the impact of multiple doses of enasidenib on the single-dose PK of sensitive probe substrates of several cytochrome P450 enzymes and transporters...
March 13, 2024: Journal of Clinical Pharmacology
https://read.qxmd.com/read/38477791/genetic-susceptibility-and-late-bone-outcomes-in-childhood-acute-lymphoblastic-leukemia-survivors
#31
JOURNAL ARTICLE
Nadeau Geneviève, Yazdanpanah Mojgan, Yazdanpanah Nahid, Forgetta Vincenzo, Girard Simon, Sinnett Daniel, Krajinovic Maja, Alos Nathalie, Manousaki Despoina
Childhood acute lymphoblastic leukemia (cALL) survivors are at increased risk for bone comorbidities, but accurate screening tools for such comorbidities are limited. Polygenic scores (PGS) could stratify cALL survivors for risk of long-term adverse bone outcomes. We evaluated 214 (51% female) cALL survivors from the Prévenir les Effets TArdifs de la LEucémie study (median age 21 yr). Bone mineral density (BMD) measurements were obtained using dual X-ray absorptiometry at the lumbar spine (LS-BMD), femoral neck (FN-BMD), and total body (TB-BMD), and vertebral fractures (VF) were documented using the vertebral deformity criterion...
January 4, 2024: Journal of Bone and Mineral Research
https://read.qxmd.com/read/38475670/comparison-of-valganciclovir-versus-foscarnet-for-the-treatment-of-cytomegalovirus-viremia-in-adult-acute-leukemia-patients-after-allogeneic-hematopoietic-cell-transplantation
#32
JOURNAL ARTICLE
Jinjin Zhu, Mimi Xu, Yuhua Ru, Huanle Gong, Yiyang Ding, Ziling Zhu, Yang Xu, Yi Fan, Xiang Zhang, Yuqing Tu, Aining Sun, Huiying Qiu, Zhengming Jin, Xiaowen Tang, Yue Han, Chengcheng Fu, Suning Chen, Xiao Ma, Feng Chen, Tiemei Song, Depei Wu, Jia Chen
Cytomegalovirus (CMV) reactivation increases treatment-related mortality (TRM) after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed 141 adult acute leukemia (AL) patients suffered allo-HCT between 2017 and 2021, who developed CMV viremia post-HCT and treated with valganciclovir or foscarnet, to evaluate effectiveness and safety of both drugs. Viremia clearance rates (14 and 21 d post treatment) and toxicities were similar in two groups. However, valganciclovir was associated with a lower cumulative incidence of CMV recurrence within 180 days (16...
March 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38473833/changes-in-the-concentrations-of-proangiogenic-cytokines-in-human-brain-glioma-and-acute-lymphoblastic-leukemia
#33
JOURNAL ARTICLE
Lukasz Oldak, Zuzanna Zielinska, Patrycja Milewska, Sylwia Chludzinska-Kasperuk, Eryk Latoch, Katarzyna Konończuk, Maryna Krawczuk-Rybak, Aleksandra Starosz, Kamil Grubczak, Joanna Reszeć, Ewa Gorodkiewicz
Acute lymphoblastic leukemia (ALL) and glioma are some of the most common malignancies, with ALL most often affecting children and glioma affecting adult men. Proangiogenic cytokines and growth factors play an important role in the development of both of these tumors. Glioma is characterized by an extremely extensive network of blood vessels, which continues to expand mainly in the process of neoangiogenesis, the direct inducers of which are cytokines from the family of vascular endothelial growth factors, i...
February 23, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38471061/gilteritinib-as-post-transplant-maintenance-for-acute-myeloid-leukemia-with-internal-tandem-duplication-mutation-of-flt3
#34
JOURNAL ARTICLE
Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Mark Litzow, John R Wingard, Esperanza B Papadopoulos, Alexander E Perl, Robert J Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K Waller, Sumithra Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Jan-Henrik Mikesch, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Nancy L Geller, Nahla Hasabou, David Delgado, Matt Rosales, Jason Hill, Stanley C Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabal, Steven M Devine, Mary M Horowitz, Yi-Bin Chen
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD ) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit...
March 12, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38468828/car-t-cell-therapy-for-t-cell-malignancies
#35
REVIEW
Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs, and multiple myeloma. These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies...
2024: Mediterranean Journal of Hematology and Infectious Diseases
https://read.qxmd.com/read/38467719/effective-treatment-of-clostridioides-difficile-infection-improves-survival-and-affects-graft-versus-host-disease-a-multicenter-study-by-the-polish-adult-leukemia-group
#36
JOURNAL ARTICLE
Agnieszka Piekarska, Alicja Sadowska-Klasa, Patrycja Mensah-Glanowska, Małgorzata Sobczyk-Kruszelnicka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Joanna Kujawska, Mateusz Wilk, Agnieszka Tomaszewska, Jan M Zaucha, Sebastian Giebel, Lidia Gil
Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes. Retrospective and prospective data of patients with CDI after allo-HCT were assessed...
March 11, 2024: Scientific Reports
https://read.qxmd.com/read/38465668/neurocognitive-outcome-and-associated-factors-in-long-term-adult-survivors-of-childhood-acute-lymphoblastic-leukemia-treated-without-cranial-radiation-therapy
#37
JOURNAL ARTICLE
Kaja Solland Egset, Jan Stubberud, Ellen Ruud, Magnus Aassved Hjort, Mary-Elizabeth Bradley Eilertsen, Anne Mari Sund, Odin Hjemdal, Siri Weider, Trude Reinfjell
OBJECTIVE: There is limited research on neurocognitive outcome and associated risk factors in long-term, adult survivors of childhood acute lymphoblastic leukemia (ALL), without treatment of cranial radiation therapy. Moreover, the impact of fatigue severity and pain interference on neurocognition has received little attention. In this cross-sectional study, we examined neurocognitive outcome and associated factors in this population. METHOD: Intellectual abilities, verbal learning/memory, processing speed, attention, and executive functions were compared to normative means/medians with one sample t tests or Wilcoxon signed-rank tests...
March 11, 2024: Journal of the International Neuropsychological Society: JINS
https://read.qxmd.com/read/38463444/-myb-overexpression-synergizes-with-the-loss-of-pten-and-is-a-dependency-factor-and-therapeutic-target-in-t-cell-lymphoblastic-leukemia
#38
JOURNAL ARTICLE
André Almeida, Sara T'Sas, Luca Pagliaro, Igor Fijalkowski, Wouter Sleeckx, Hannah Van Steenberge, Raffaella Zamponi, Béatrice Lintermans, Wouter Van Loocke, Bruno Palhais, Alexandra Reekmans, Valentina Bardelli, Lisa Demoen, Lindy Reunes, Dieter Deforce, Filip Van Nieuwerburgh, Alex Kentsis, Panagiotis Ntziachristos, Nadine Van Roy, Barbara De Moerloose, Cristina Mecucci, Roberta La Starza, Giovanni Roti, Steven Goossens, Pieter Van Vlierberghe, Tim Pieters
T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that accounts for 10%-15% of pediatric and 25% of adult ALL cases. Although the prognosis of T-ALL has improved over time, the outcome of T-ALL patients with primary resistant or relapsed leukemia remains poor. Therefore, further progress in the treatment of T-ALL requires a better understanding of its biology and the development of more effective precision oncologic therapies. The proto-oncogene MYB is highly expressed in diverse hematologic malignancies, including T-ALLs with genomic aberrations that further potentiate its expression and activity...
March 2024: HemaSphere
https://read.qxmd.com/read/38462215/pre-transplant-blinatumomab-improves-outcomes-in-b-cell-acute-lymphoblastic-leukemia-patients-who-undergo-allogeneic-hematopoietic-cell-transplantation
#39
JOURNAL ARTICLE
Ayman Sayyed, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H Lipton, Fotios V Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic
BACKGROUND: Blinatumomab, a bispecific monoclonal antibody, effectively controls refractory B-cell acute lymphoblastic leukemia (ALL) and promotes measurable residual disease (MRD) negativity. This study investigated the impact of pre-transplant blinatumomab on allogeneic hematopoietic cell transplantation (HCT) outcomes in B-cell ALL patients. METHODS: We analyzed the effect of pre-transplant blinatumomab on transplant outcomes of 117 adults undergoing allogeneic HCT for B-cell ALL at Princess Margaret Hospital, Toronto, between 2010 and 2021...
March 8, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38460433/efficacy-and-safety-of-mitoxantrone-etoposide-and-cytarabine-for-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia
#40
JOURNAL ARTICLE
Sharon Zhong, Heena Kurish, Robert Walchack, Hong Li, Jessi Edwards, Abhay Singh, Anjali Advani
BACKGROUND/RATIONALE: Most patients with acute myeloid leukemia (AML) develop relapsed or refractory (R/R) disease after receiving initial induction chemotherapy. Salvage chemotherapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative therapy for R/R AML. Mitoxantrone, etoposide, and cytarabine (MEC) is the current standard of care salvage regimen for R/R AML at Cleveland Clinic. The primary objective was to determine the overall remission rate (ORR: defined as patients achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi)) in R/R AML patients who received MEC...
April 2024: Leukemia Research
keyword
keyword
90903
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.